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Identifying and Validating New Drug Targets for Stroke and Beyond: Can Mendelian Randomization 
Help?  
Andrew Plump, MD, PhD 
George Davey Smith, MD, DSc, FRS 
Until very recently, drug discovery attrition rates have been increasing.1 This poor return on investment 
in biopharmaceutical R&D can be explained by scientific and extra-scientific influences. Regulatory, payer 
and commercial forces incentivized pharmaceutical companies to focus on common diseases and 
incremental improvements on existing mechanisms. The majority of resources within pharmaceutical 
companies have traditionally been focused on small molecule drug discovery programs, reflecting a 
“hammer and a nail” mindset, with small-molecule chemistry as the hammer and the nail a classically 
defined “druggable” target. Rather than starting with a target based on strong human biological rationale, 
targets have been selected based on their ability to be “drugged” by a medicinal chemist. Compounding 
this problem has been an inadequate understanding of disease biology and an overreliance on animal 
models of human disease. 
Drug discovery is a long and complex process. Decisions made in discovery -- where costs are relatively 
modest, have major downstream effects in development, where costs increase exponentially. Today, the 
convergence of an innovation-friendly environment, a greater focus on translational science and the 
emergence of powerful new therapeutic modalities beyond synthetic small molecules has led to dramatic 
shifts in approach, a greater focus on transformative therapies and a gradual, but meaningful, uptick in 
success rates.2 Given the long life-cycle of drug discovery, success metrics lag behind progress, however, 
we have begun to see a turn-around in attrition as evidenced by both apparent improvements in return 
on investment and United States Food and Drug Administration (FDA) approval rates. 
How is innovation being driven by this intersection of extra-scientific factors, translational science and 
new treatment modalities? First, key stakeholders now demand innovation. Increasingly, payers will only 
reimburse new medicines that are innovative and regulatory agencies have created frameworks to 
accelerate the development of truly innovative new medicines, such as the FDA Breakthrough Therapy, 
the European Medicines Agency (EMA) PRIority Medicines (PRIME) scheme, and Japan’s Pharmaceuticals 
and Medical Devices Agency (PMDA) Sakigake designation. 3 Commercial organizations within healthcare 
companies fully support an innovation agenda with potential patient population size no longer solely 
driving commercial models. While drug pricing is a hot-button issue for society, there is general agreement 
that an incentive system must exist to reward innovation within the smaller rare and specialty care 
populations. A willingness to reimburse new therapies for smaller populations has enabled both small and 
large companies to focus on more homogeneous disease segments where much larger effect sizes and 
vastly improved therapeutic indices may be seen. 
A powerful and exciting shift in the focus of drug discovery is occurring as we aspire beyond disease 
management to normalization and cure. This trend has been enabled by the dramatic progress in our 
molecular understanding of disease and the emergence of novel modalities.  
Human validation of a therapeutic target, realized by the emergence of a successful first drug against such 
a target, is the most compelling and “safest” rationale for another drug discovery program against the 
same target. This explains the historical focus on next-generation -- and in many cases undifferentiated 
or “me-too” therapies, as we have seen repeatedly for cardiovascular diseases with classes such as the 
statins, angiotensin pathway modifiers and calcium channel blockers. 
Human pharmacological validation for a target has limitations, whereas human genetics offers broad 
value and has emerged as the most compelling tool for new target identification, opening truly novel 
therapeutic approaches for diseases with large unmet medical need, often absent any existing treatments. 
A human genetic association demonstrating causality for a disease greatly increases the likelihood of 
success for a drug engaging the target encoded by the cognate gene, given a more direct link to causality 
than many other modes of investigation. Retrospective studies have proven that this is indeed the case.4, 
5 The majority of existing drugs act on targets that have human genetic associations to Mendelian and 
common genetic variations, which are often identical or similar to a disease of interest. Discovery 
organizations in large and small biopharmaceutical companies use human genetics as a primary motivator 
for research investments. This is especially true for classical Mendelian diseases, which are genetically 
transmitted and for which we now have more than 60 FDA-approved therapies that directly target the 
underlying genetic anomaly.6 This is also true for more common diseases where both Mendelian and 
population genetics have substantially improved our probability of success. 
With the growing availability of large-scale genomic and phenotypic data over the past several years, more 
subtle genetic instruments have been developed. Mendelian randomization, in particular, has emerged 
as a powerful tool for drug discovery. Mendelian randomization provides an opportunity to interrogate 
nature’s version of a randomized controlled clinical trial,7-9 by using genetic variation to estimate the 
causal effect of an intermediate marker on clinical disease. The power of this methodology to drug 
discovery is best illustrated by two Mendelian randomization stories: PCSK9 and C reactive protein (CRP).  
Both loss- and gain-of-function genetic variation has been identified in the PCSK9 gene. These genetic 
variants associate strongly with circulating PCSK9 and LDL-cholesterol (LDL-C) levels, which associate 
strongly with coronary artery disease (CAD), consistent with a large body of epidemiological evidence. The 
genetics of PCSK9 was the driver of multiple drug discovery efforts aimed at identifying PCSK9 inhibitors, 
of which two therapies are now approved with clinically verified cardiovascular protection, exactly as 
predicted by the PCSK9 Mendelian randomization experiment.10 Likewise, genetic variation in the CRP 
gene associates with circulating CRP levels; however, these genetic variants and their associated 
differences in CRP level do not relate to CAD risk. Despite a strong epidemiological association between 
circulating CRP levels and CAD, we conclude from the Mendelian randomization studies that CRP is not 
causal and thus, while a predictive biomarker of CAD, not a therapeutic drug target.11 Today CRP is 
recognized clearly as an inflammatory biomarker, prior to the Mendelian randomization studies excluding 
it as a therapeutic target, there were multiple industry drug discovery efforts underway. 
In this edition of Circulation, Chong et al. publish a Mendelian randomization study designed to identify 
new stroke targets.12 The authors employ a hypothesis-generating screen leveraging genome-wide 
association studies (GWAS) and large-scale plasma protein analysis to search for genes and putative causal 
biomarkers for ischemic stroke. Unlike the targeted approaches used to validate PCSK9 and invalidate CRP 
as therapeutic targets, this study takes a completely untargeted approach examining the genome and 653 
circulating plasma proteins as possible causal factors for large artery atherosclerotic, cardioembolic and 
small artery occlusive stroke. The study then examines the association of “hits” for ischemic stroke 
subtypes with intracranial bleeding and subarachnoid hemorrhage. Hits were next evaluated in a 
Mendelian randomization phenome-wide association study (MR-PheWAS) across 679 diseases to 
understand the pleiotropic effects of these targets and to serve as proxy measures of potential safety 
issues for drugs modulating these targets. 
For ischemic stroke, Chong et al. identified seven potentially causal biomarkers with evidence above a 
multiple-testing corrected threshold: five known and two novel. Among the known biomarkers were the 
coagulation factor, Factor XI (F11), and the apolipoprotein, lipoprotein(a) (LPA), both of which were 
associated with large artery atherosclerotic disease, an association that would be expected based on 
known biology and previous human genetic associations with other atherosclerotic diseases. While the 
associations with known targets do not offer new insights into drug discovery – in fact, there are ongoing 
drug development programs for both targets – they validate the author’s approach. 
The two novel observations were with respect to cardioembolic stroke (CES). The stronger of the two 
associations is for TWEAK (TNFS12), a circulating tumor necrosis factor (TNF)-like cytokine with a range of 
biological activities. Unfortunately, TWEAK had a directionally opposite association with subarachnoid 
hemorrhage and multiple deleterious associations identified in the MR-PheWAS, therefore safety 
concerns make this a less than desirable therapeutic target. 
The second novel biomarker identification was with SCARA5, a gene that encodes a scavenger receptor 
for Ferritin that mediates non-transferrin-dependent delivery of iron.12 SCARA5 had a suggested 
protective effect for both CES and subarachnoid hemorrhage in this study. In addition, there was a trend 
for protection against intraventricular hemorrhage and no clear deleterious associations in the MR-
PheWAS. 
Is SCARA5 a compelling therapeutic target for stroke? Not now.  Replication is critical for human genetic 
studies. Genetic variation in SCARA5 accounts for very little of the circulating SCARA5 levels and the 
association between SCARA5 and stroke had the lowest level of statistical evidence of the seven 
biomarkers. Additionally, methodological issues may affect the robustness of the conclusions. First, the 
authors pruned SNPs at a linkage disequilibrium r2 of <0.10, which by no means guarantees generation of 
a set of “independent” variants.  This means that double counting of the same signal is possible, and 
importantly that the different variants will have the same biases, rendering ineffective the multiple variant 
approaches to sensitivity analyses for horizonal pleiotropy.13  In this situation, for example, the InSIDE 
assumption of MR-Egger would be violated.  Second, the MR-RAPS method is not robust to unbalanced 
horizonal pleiotropy.  In general, the statements made several times in the paper that “there was no 
evidence of horizontal pleiotropy” cannot be accepted on the basis of the data provided.  Simply put, 
based on the methodology used by Chong et al., we cannot conclude that the association of the SCARA5 
gene to CES is due to SCARA5 variation or that of some other factor linked to these genetic variants. 
If we suspend judgment on the statistical methodology and accept the association as replicable and true, 
is SCARA5 then a viable drug discovery target?  Still, not at this time. Human genetics offers insights into 
causality but ultimately the prosecution of a drug discovery program requires a deep understanding of 
function. What protein activity is driving disease? In what cellular compartment is this activity most 
relevant? The rapidity in moving from PCSK9 genetic association to a mechanistic understanding of how 
PCSK9 ultimately affects LDL-C was atypical, but built from a deep understanding of cholesterol 
biosynthesis and LDL-receptor biology and regulation. We are not in the same place with SCARA5 biology. 
SCARA5 is a type II single transmembrane crossing protein receptor. Is circulating SCARA5 involved in CES 
causality or is it a proxy for cell surface activity? There are Mendelian randomization precedents for 
associations of cell surface receptors with human disease, most notably the IL6-receptor. Variation in the 
IL6 receptor gene influences circulating levels of IL6 and receptor-mediated effects in such a way that 
provides a coherent picture as to how biological activity of the pathway influences cardiovascular disease 
risk,14, 15 which received subsequent support from RCT evidence.16 A substantial body of mechanistic work 
is needed to better understand the function of SCARA5 and how one might modulate this target. 
Additionally, the broad expression of SCARA5 in the epithelium of multiple tissues suggests the potential 
for untoward safety issues. The MR-PheWAS suggests that low-level modulation of SCARA5 might not 
associate with other disease states, but what safety issues might emerge following the more potent 
knockdown that is likely necessary to elicit the therapeutic benefits of a drug? The identification of 
humans with SCARA5 deficiency could provide additional confidence in safety (and efficacy) of targeting 
SCARA5. We must also ask what disease we are targeting. CES is a heterogeneous disease often caused 
by atrial-fibrillation, so what is the subpopulation that we would target by modulating SCARA5? An 
understanding of disease causality is the obvious start of any drug discovery program, but an equal 
consideration is the targeted population and the endpoints that will be used to establish dose, proof of 
principle, regulatory approval and payer reimbursement. 
The future of target identification clearly lies in large-scale, information-rich human genetic studies. With 
more sophisticated tools such as Mendelian randomization and the next-generation methodologies that 
build on these principles, we are enhancing our ability to identify reliable drug targets, biomarkers that 
can guide decision making in early drug development and patient segments most amenable to therapeutic 
intervention. Translating novel findings in Mendelian randomization studies into next generation 
therapies will require substantial evolution in our ability to explore these newly identified targets with 
tools that transform them into plausible experimental agents worthy of substantial investment. 
Figure 1.  Human Genetics can be a powerful source for drug target identification. Mendelian 
randomization can provide robust instruments for new target identification and biomarker discovery.  
When used with a vast array of phenotypic data, Mendelian randomization (termed Mendelian 
randomization phenome-wide association studies or MR-PheWAS) can offer clues to the potential adverse 
effects of a drug against a genetically identified target.  Once there is high confidence that modulation of 
a genetic target could benefit patients with (or at risk of) a given disease, there is still work to be done.  A 
mechanistic understanding of disease association and a deep understanding of protein function are 
necessary for any drug discovery program. 
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